130 related articles for article (PubMed ID: 6589165)
1. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.
Weenen H; van Maanen JM; de Planque MM; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):919-26. PubMed ID: 6589165
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
3. Sensitive and specific determination of the new anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid chromatography.
Deesen PE; Leyland-Jones B
Drug Metab Dispos; 1984; 12(1):9-13. PubMed ID: 6141919
[TBL] [Abstract][Full Text] [Related]
4. Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography.
Weenen H; Osterop AP; van der Poort SE; Lankelma J; van der Vijgh WJ; Pinedo HM
J Pharm Sci; 1986 Dec; 75(12):1201-4. PubMed ID: 3470504
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of epidoxorubicin in animals: absence of glucuronidation.
Maessen PA; Mross KB; Pinedo HM; van der Vijgh WJ
Cancer Chemother Pharmacol; 1987; 20(1):85-7. PubMed ID: 3476219
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.
van der Vijgh WJ; Maessen PA; Pinedo HM
Cancer Chemother Pharmacol; 1990; 26(1):9-12. PubMed ID: 2322993
[TBL] [Abstract][Full Text] [Related]
7. Separation, characterization, and analysis of epirubicin (4'-epidoxorubicin) and its metabolites from human urine.
Cassinelli G; Configliacchi E; Penco S; Rivola G; Arcamone F; Pacciarini A; Ferrari L
Drug Metab Dispos; 1984; 12(4):506-10. PubMed ID: 6148220
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 4'-epi-doxorubicin in man.
Weenen H; Lankelma J; Penders PG; McVie JG; ten Bokkel Huinink WW; de Planque MM; Pinedo HM
Invest New Drugs; 1983; 1(1):59-64. PubMed ID: 6590528
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.
Vrignaud P; Eghbali H; Hoerni B; Iliadis A; Robert J
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1307-13. PubMed ID: 3865777
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
Behnia K; Boroujerdi M
J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
12. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
Ramanathan-Girish S; Boroujerdi M
J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes.
Beulz-Riche D; Robert J; Menard C; Ratanasavanh D
Fundam Clin Pharmacol; 2001 Dec; 15(6):373-8. PubMed ID: 11860524
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
[TBL] [Abstract][Full Text] [Related]
15. N-acetylbenzidine-N'-glucuronidation by human, dog and rat liver.
Babu SR; Lakshmi VM; Hsu FF; Kane RE; Zenser TV; Davis BB
Carcinogenesis; 1993 Dec; 14(12):2605-11. PubMed ID: 8269633
[TBL] [Abstract][Full Text] [Related]
16. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation of the enantiomers of E-10-hydroxynortriptyline in human and rat liver microsomes.
Dumont E; von Bahr C; Perry TL; Bertilsson L
Pharmacol Toxicol; 1987 Nov; 61(5):335-41. PubMed ID: 3125532
[TBL] [Abstract][Full Text] [Related]
18. Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.
Cummings J; Willmott N; More I; Kerr DJ; Morrison JG; Kaye SB
Biochem Pharmacol; 1987 May; 36(9):1521-6. PubMed ID: 3579988
[TBL] [Abstract][Full Text] [Related]
19. Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system.
Dodion P; Akman SR; Tamburini JM; Riggs CE; Colvin OM; Bachur NR
J Pharmacol Exp Ther; 1986 Apr; 237(1):271-4. PubMed ID: 3514847
[TBL] [Abstract][Full Text] [Related]
20. Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.
Maessen PA; Mross KB; Pinedo HM; van der Vijgh WJ
J Chromatogr; 1987 Jul; 417(2):339-46. PubMed ID: 3477566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
